Aimmune Therapeutics Files Registration Statement For Initial Public Offering

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Aimmune Therapeutics has applied to list its common stock under the symbol “AIMT” on The NASDAQ Global Market.

Help employers find you! Check out all the jobs and post your resume.

Back to news